Transmembrane domain targeting peptide antagonizing ErbB2/Neu inhibits breast tumor growth and metastasis

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Despite advances in targeted therapies, breast cancer relapse and metastasis remain significant challenges.
• Existing treatments often target extracellular ligands or receptor subunits of tyrosine kinases like ErbB2.
• Novel therapeutic strategies are crucial to combat aggressive breast cancer phenotypes.

Purpose of the Study:

• To investigate the anticancer potential of small peptides targeting the transmembrane domain of epidermal growth factor receptor 2 (ErbB2).
• To evaluate the efficacy of these peptides in reducing ErbB2 phosphorylation, downstream signaling, and tumor progression in a preclinical breast cancer model.

Main Methods:

• Development and application of small peptides designed to interact with the ErbB2 transmembrane domain.
• Utilizing a genetically engineered mouse model of breast cancer for in vivo efficacy studies.
• Employing various assays to assess peptide specificity, target engagement (ErbB2 phosphorylation, Akt signaling), tumor cell proliferation, survival, and metastatic activity (microcomputed tomography).

Main Results:

• Peptides demonstrated specificity for ErbB2 and induced long-term reduction in ErbB2 phosphorylation and Akt signaling.
• Treatment led to decreased tumor cell proliferation and increased survival rates in the mouse model.
• Microcomputed tomography confirmed the antimetastatic activity and impact on primary tumor growth.

Conclusions:

• Small peptides targeting the ErbB2 transmembrane domain exhibit significant anticancer and antimetastatic properties.
• The intracellular domain of the cell membrane represents a novel and underexplored target for therapeutic intervention in breast cancer.
• This approach offers a promising new dimension for developing innovative breast cancer drugs.